Camilla SimpsonCEO at Zehna Therapeutics IncSpeaker
Profile
Camilla Simpson has over 25 years of business and strategy experience across a diverse group of organizations: from seed investments to public companies. Camilla has demonstrated a proven track record in delivering novel products for multiple disease indications to global markets in areas of high unmet medical need throughout her career. Currently, Camilla is CEO of Zehna Therapeutics, Inc a seed stage startup and spin out of the Cleveland Clinic. Prior to this, Camilla founded Rare Strategic LLC where she provided strategic advice to early stage venture-backed companies. Camilla has held numerous executive leadership positions, including SVP, Head of Product Portfolio Development at BioMarin Pharmaceutical Inc., Global Head of Regulatory Affairs at BioMarin Pharmaceutical Inc., and VP Global Regulatory Strategy- Early Development and Business Development at Shire Pharmaceuticals. During her career she has been responsible for the registration of 8 products and played a key role in 5 M&A's.